Intellia pauses dosing in Phase 3 MAGNITUDE trials after Grade 4 liver event in one patient

Intellia Therapeutics, Inc.

Patient dosed on Sept 30, 2025, experienced Grade 4 liver transaminases and increased total bilirubin on Oct 24.
Patient hospitalized and receiving medical intervention; Intellia consulting experts and regulators.
Pause affects both MAGNITUDE (ATTR-CM, >650 enrolled) and MAGNITUDE-2 (ATTR-PN, 47 enrolled) trials.
Over 450 patients estimated to have been dosed with nex-z across both trials to date.
Conference call scheduled at 8:30 a.m. ET today to discuss the update.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.